---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-280757"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:02:59.122910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO

## Summary
- Net product sales of FYARRO $4.2M in Q3 2022, up 24% from Q2; net loss $14.5M (vs $87.1M in Q3 2021).
- Cash $183M as of Sep 30, 2022; cash runway extended into 2025 after $72.5M PIPE financing.
- Founder/CEO Neil Desai appointed Executive Chairman; COO Brendan Delaney succeeds as President & CEO effective Jan 1, 2023.
- Delaney receives $624K base salary, 60% bonus target, option for 150K shares; Board expanded to 8.
- PRECISION 1 trial on track for preliminary data H1 2023; Mirati collaboration on adagrasib/nab-sirolimus combo expected H1 2023.

## SEC filing metadata
- accession: 0001193125-22-280757
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/d317786d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-280757
- JSON: https://secwatch.observer/filing/0001193125-22-280757.json
- Plain text: https://secwatch.observer/filing/0001193125-22-280757.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million, net income Net loss for the three months ended September 30, 2022 was $14.5 million.
  - Period: the third quarter of 2022
  - Revenue: $4.2 million
  - Net income: Net loss for the three months ended September 30, 2022 was $14.5 million
  - Result: reported results
  source text: data in the first half of 2023. • Grew FYARRO net product sales . For the three months ended September 30, 2022, net product sales of FYARRO showed continued growth, ending with $4.2 million in sales in the third quarter, a 24% increase over the second quarter. • Leadership transition. Current CEO, Dr. Neil Desai, has been appointed Executive Chairman,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm
- Executive change
  Brendan Delaney was elected as Director at Whitehawk Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm
- Executive change
  Brendan Delaney was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm
- Executive change
  Neil Desai was appointed as Executive Chairman at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.